JP7085644B2 - Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 - Google Patents

Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 Download PDF

Info

Publication number
JP7085644B2
JP7085644B2 JP2020562067A JP2020562067A JP7085644B2 JP 7085644 B2 JP7085644 B2 JP 7085644B2 JP 2020562067 A JP2020562067 A JP 2020562067A JP 2020562067 A JP2020562067 A JP 2020562067A JP 7085644 B2 JP7085644 B2 JP 7085644B2
Authority
JP
Japan
Prior art keywords
cells
fusion protein
cancer
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511081A (ja
Inventor
チャン・ミョンホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GI Innovation Inc
Original Assignee
GI Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GI Innovation Inc filed Critical GI Innovation Inc
Publication of JP2021511081A publication Critical patent/JP2021511081A/ja
Priority to JP2022070213A priority Critical patent/JP7569820B2/ja
Application granted granted Critical
Publication of JP7085644B2 publication Critical patent/JP7085644B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020562067A 2018-09-17 2019-09-16 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 Active JP7085644B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022070213A JP7569820B2 (ja) 2018-09-17 2022-04-21 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR10-2018-0110698 2018-09-17
KR20180110698 2018-09-17
KR10-2019-0001867 2019-01-07
KR20190001867 2019-01-07
US201962832013P 2019-04-10 2019-04-10
US62/832,013 2019-04-10
KR10-2019-0053436 2019-05-08
KR20190053436 2019-05-08
PCT/KR2019/011928 WO2020060122A1 (ko) 2018-09-17 2019-09-16 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022070213A Division JP7569820B2 (ja) 2018-09-17 2022-04-21 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Publications (2)

Publication Number Publication Date
JP2021511081A JP2021511081A (ja) 2021-05-06
JP7085644B2 true JP7085644B2 (ja) 2022-06-16

Family

ID=69887592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562067A Active JP7085644B2 (ja) 2018-09-17 2019-09-16 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
JP2022070213A Active JP7569820B2 (ja) 2018-09-17 2022-04-21 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022070213A Active JP7569820B2 (ja) 2018-09-17 2022-04-21 Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Country Status (22)

Country Link
US (4) US11492384B2 (https=)
EP (2) EP3715367B1 (https=)
JP (2) JP7085644B2 (https=)
KR (2) KR102201086B1 (https=)
CN (2) CN111971295B (https=)
AU (1) AU2019343850B2 (https=)
CA (1) CA3086486A1 (https=)
CL (1) CL2020001872A1 (https=)
DK (1) DK3715367T3 (https=)
ES (1) ES2985387T3 (https=)
FI (1) FI3715367T3 (https=)
HU (1) HUE068059T2 (https=)
IL (1) IL275592B (https=)
MX (1) MX2020007072A (https=)
PE (1) PE20201418A1 (https=)
PH (1) PH12020551026A1 (https=)
PL (1) PL3715367T3 (https=)
PT (1) PT3715367T (https=)
SG (1) SG11202005873QA (https=)
TW (2) TWI755630B (https=)
WO (1) WO2020060122A1 (https=)
ZA (1) ZA202003645B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022115876A (ja) * 2018-09-17 2022-08-09 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (ru) * 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
KR102351020B1 (ko) * 2019-11-20 2022-01-14 주식회사 지아이셀 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법
AU2020389422B2 (en) * 2019-11-20 2024-08-08 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
US20230014358A1 (en) * 2019-11-27 2023-01-19 Gi Cell, Inc. Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein
IL292935A (en) * 2019-11-27 2022-07-01 Gi Cell Inc A compound for anti-cancer treatment, which includes nk cells and a fusion protein including il-2 protein and cd80 protein
JP7697959B2 (ja) 2020-03-18 2025-06-24 ジーアイ イノベーション， インコーポレイテッド Ｉｌ－２タンパク質とｃｄ８０タンパク質を含む融合タンパク質製剤
KR102440962B1 (ko) * 2020-03-18 2022-09-07 ㈜지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
KR20210117208A (ko) * 2020-03-18 2021-09-28 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
CN115943165A (zh) * 2020-05-25 2023-04-07 北京比洋生物技术有限公司 Fc-CD80融合蛋白和其缀合物以及它们的用途
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
EP4174088A4 (en) * 2020-06-30 2024-01-24 GI Innovation, Inc. FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF
US20230235005A1 (en) * 2020-07-02 2023-07-27 Inhibrx, Inc. Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
WO2022045849A1 (ko) * 2020-08-31 2022-03-03 주식회사 지아이셀 Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023552810A (ja) * 2020-12-08 2023-12-19 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 抗ｅｇｆｒキメラ抗原受容体
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
WO2022057696A2 (zh) * 2021-09-08 2022-03-24 中南大学湘雅医院 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法
KR20230168273A (ko) * 2022-06-03 2023-12-13 (주)지아이이노베이션 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도
WO2023249425A1 (ko) * 2022-06-22 2023-12-28 ㈜지아이이노베이션 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN119997963A (zh) * 2022-09-20 2025-05-13 南韩商Gi生物群系公司 植物乳杆菌菌株的联合疗法及利用该菌株的癌症治疗方法
JP2025534272A (ja) * 2022-09-20 2025-10-15 ジーアイ バイオム インコーポレイテッド ラクトバチルス・プランタルム菌株の併用療法及びそれを用いた癌の治療方法
CN115850436B (zh) * 2022-10-14 2026-02-03 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2025063755A1 (ko) * 2023-09-20 2025-03-27 주식회사 에스엘바이젠 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515251A (ja) 1998-05-21 2002-05-28 キャンサー リサーチ ベンチャーズ リミテッド 遍在性エンドプロテアーゼを用いた開裂によるキメラ融合タンパク質からの複数の遺伝子産物の生成
JP2014500868A (ja) 2010-11-12 2014-01-16 セントロ ド インムノロジア モレキュラー 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド
JP2014506793A (ja) 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−２ポリペプチド
US20170145071A1 (en) 2015-11-02 2017-05-25 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA842025B (en) * 1983-03-21 1984-11-28 Hoffmann La Roche Interleuken-2
CN86104525A (zh) * 1985-07-31 1987-02-25 武田药品工业株式会社 人类白细胞介素-2的分析方法和试剂
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
CU23229A1 (es) 2002-05-10 2007-09-26 Ct Ingenieria Genetica Biotech ANTAGONISTA QUIMéRICO ANTH1
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP2402754B2 (en) * 2006-03-06 2023-07-26 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US20140377253A1 (en) * 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
DK3186283T3 (da) 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
US11492384B2 (en) 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515251A (ja) 1998-05-21 2002-05-28 キャンサー リサーチ ベンチャーズ リミテッド 遍在性エンドプロテアーゼを用いた開裂によるキメラ融合タンパク質からの複数の遺伝子産物の生成
JP2014500868A (ja) 2010-11-12 2014-01-16 セントロ ド インムノロジア モレキュラー 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド
JP2014506793A (ja) 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−２ポリペプチド
US20170145071A1 (en) 2015-11-02 2017-05-25 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lucas Chan et al.，IL-2/B7.1 (CD80) Fusagene Transduction of AML Blasts by a Self-Inactivating Lentiviral Vector Stimulates T Cell Responses in Vitro: a Strategy to Generate Whole Cell Vaccines for AML，MOLECULAR THERAPY，2005年，Vol.11, No.1，pp.120-131
Tania Carmenate et al.，Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2，The Journal of Immunology，2013年，Vol.190, No.12，pp.6230-6238

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022115876A (ja) * 2018-09-17 2022-08-09 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
JP7569820B2 (ja) 2018-09-17 2024-10-18 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用

Also Published As

Publication number Publication date
JP2021511081A (ja) 2021-05-06
TWI755630B (zh) 2022-02-21
PT3715367T (pt) 2024-07-25
CN111971295A (zh) 2020-11-20
KR20200032009A (ko) 2020-03-25
AU2019343850B2 (en) 2024-06-06
IL275592B (en) 2022-02-01
EP3715367B1 (en) 2024-06-12
US20220380781A1 (en) 2022-12-01
PE20201418A1 (es) 2020-12-09
BR112020015030A2 (pt) 2021-03-16
EP4403635A3 (en) 2024-09-18
JP7569820B2 (ja) 2024-10-18
DK3715367T3 (da) 2024-07-29
IL275592A (en) 2020-08-31
TWI824258B (zh) 2023-12-01
PL3715367T3 (pl) 2024-09-02
EP3715367A4 (en) 2021-05-05
JP2022115876A (ja) 2022-08-09
ES2985387T3 (es) 2024-11-05
TW202028227A (zh) 2020-08-01
CL2020001872A1 (es) 2020-12-18
CN111971295B (zh) 2024-08-02
US20250230212A1 (en) 2025-07-17
US20200369740A1 (en) 2020-11-26
KR102201086B1 (ko) 2021-01-11
AU2019343850A1 (en) 2020-06-25
WO2020060122A1 (ko) 2020-03-26
US12291555B2 (en) 2025-05-06
SG11202005873QA (en) 2020-07-29
EP3715367A1 (en) 2020-09-30
KR20210008110A (ko) 2021-01-20
KR102201086B9 (ko) 2022-10-21
TW202136288A (zh) 2021-10-01
MX2020007072A (es) 2020-11-11
KR102558191B1 (ko) 2023-07-24
CA3086486A1 (en) 2020-03-26
FI3715367T3 (fi) 2024-07-23
ZA202003645B (en) 2022-09-28
EP4403635A2 (en) 2024-07-24
US20220389070A1 (en) 2022-12-08
PH12020551026A1 (en) 2021-09-06
HUE068059T2 (hu) 2024-12-28
CN118725141A (zh) 2024-10-01
US11492384B2 (en) 2022-11-08
US12286464B2 (en) 2025-04-29

Similar Documents

Publication Publication Date Title
JP7085644B2 (ja) Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
JP7699833B2 (ja) Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質および免疫チェックポイント抑制剤を含む癌治療用医薬組成物
US20240400640A1 (en) Fusion protein dimer including pd-1 and il-21, and use thereof
US20230104217A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
RU2828377C1 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая слитый белок, содержащий белок il-2 и белок cd80, и ингибитор иммунной точки контроля
RU2811541C2 (ru) Слитый белок, включающий белок il-2 и белок cd80, и его применение
BR112020015030B1 (pt) Proteína de fusão compreendendo il-2 e cd80, dímero da dita proteína, usos dos mesmos para tratar câncer, bem como polinucleotídeo, vetor, microorganismo transformado e composição farmacêutica
BR122024021342A2 (pt) Proteína de fusão compreendendo il-2 e cd80, dímero da dita proteína, usos dos mesmos para tratar câncer ou uma doença infecciosa, bem como polinucleotídeo, vetor, célula transformada e composição farmacêutica
HK40032574A (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
HK40032574B (zh) 包含il-2蛋白和cd80蛋白的融合蛋白及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220421

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220502

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220606

R150 Certificate of patent or registration of utility model

Ref document number: 7085644

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250